Fly News Breaks for June 14, 2019
Jun 14, 2019 | 05:50 EDT
After hosting investor meetings with management, Piper Jaffray analyst Matt O'Brien calls Merit Medical Systems a "must own mid-cap name." The analyst does not believe investors understand that the company has passed a point now with hospitals where they view Merit as an "excellent partner with high quality products at the scale needed to be awarded more sole source and national contracts." This dynamic and a "sound" acquisition strategy should, according to management, result in sales growing from $1B in 2019 up to $2B in the next five-to-seven years, O'Brien tells investors in a research note. He reiterates an Overweight rating on Merit Medical with a $75 price target.
News For MMSI From the Last 2 Days
There are no results for your query MMSI